April 27, 2017 3:04 PM ET

Pharmaceuticals

Company Overview of Endocyte, Inc.

Company Overview

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company’s products in pre-clinical development include EC2629, a folate receptor-t...

3000 Kent Avenue

Suite A1-100

West Lafayette, IN 47906

United States

Founded in 1995

76 Employees

Phone:

765-463-7175

Fax:

765-463-9271

Key Executives for Endocyte, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $372.5K
Co-Founder, Chief Science Officer and Director
Age: 68
Total Annual Compensation: $228.1K
Chief Medical Officer
Age: 52
Total Annual Compensation: $349.0K
Vice President of Human Resources
Age: 51
Total Annual Compensation: $256.9K
Vice President of Research & Development
Age: 50
Total Annual Compensation: $328.9K
Compensation as of Fiscal Year 2016.

Endocyte, Inc. Key Developments

Endocyte, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016

Endocyte, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported, collaboration revenue of $12,000, loss from operations of $9,901,000, net loss of $9,794,000, compared to collaboration revenue of $12,000, loss from operations of $11,272,000, net loss of $11,065,000, for the same period a year ago. Net loss per share - basic and diluted was $0.23 against $0.26 a year ago. For the year, the company reported, collaboration revenue of $70,000, loss from operations of $41,973,000, net loss of $41,270,000, compared to collaboration revenue of $70,000, loss from operations of $44,720,000, net loss of $43,888,000, for the same period a year ago. Net loss per share - basic and diluted was $0.98 against $1.04 a year ago.

Endocyte and Seattle Children’S Research Institute to Collaborate on Endocyte’s Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for Car T-Cell Therapies

Endocyte, Inc. announced their plan to collaborate with Seattle Children’s Research Institute and Dr. Michael Jensen for the development of Endocyte’s SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte’s proprietary SMDC bi-specific adaptor molecules. The aim of the research collaboration is to join Endocyte’s SMDC bi-specific adaptor technology with the CAR T-cell immunotherapy research efforts at the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, to move these potentially enabling technologies more quickly to patients in the clinic. Dr. Jensen, a recognized leader in the field of CAR T-cell research, is the director of Ben Towne Center for Childhood Cancer Research and the Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research at Seattle Children’s Research Institute, and a professor of hematology-oncology at the University of Washington School of Medicine.

Endocyte, Inc., Q4 2016 Earnings Call, Mar 10, 2017

Endocyte, Inc., Q4 2016 Earnings Call, Mar 10, 2017

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Endocyte, Inc., please visit www.endocyte.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.